Last reviewed · How we verify

Bupivacaine SNB

Pacira Pharmaceuticals, Inc · FDA-approved active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local anesthesia for infiltration, nerve block, and regional anesthesia procedures, Postoperative pain management via nerve block.

At a glance

Generic nameBupivacaine SNB
Also known asBupivacaine
SponsorPacira Pharmaceuticals, Inc
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine reversibly binds to and inactivates voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby preventing depolarization and action potential propagation. This results in local anesthesia and loss of sensation in the infiltrated tissue. SNB (Selective Nerve Block) formulations are designed for prolonged regional anesthesia with improved safety profiles.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: